X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Approvals - 20/Aug 21:08

FDA Approves Rybrevant (amivantamab-vmjw) Plus Lazcluze (lazertinib) for Patients with EGFR-Mutated Advanced Lung cancer

RARITAN, N.J., Aug. 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Rybrevant® (amivantamab-vmjw) plus Lazcluze™ (lazertinib) for the first-line treatment...

Articles similaires

Sorry! Image not available at this time

FDA Approves Ebglyss (lebrikizumab-lbkz) for the Treatment of Atopic Dermatitis

drugs.com - 13/Sep 00:09

INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved...

Sorry! Image not available at this time

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

drugs.com - 13/Sep 07:09

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Sorry! Image not available at this time

Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis

drugs.com - 13/Sep 07:09

HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved...

Sorry! Image not available at this time

FDA Approves Tremfya for Ulcerative Colitis

drugs.com - 22:24

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

Sorry! Image not available at this time

FDA Approves Tremfya for Ulcerative Colitis

drugs.com - 22:24

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to...

Sorry! Image not available at this time

FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

drugs.com - 12/Sep 08:09

South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S....

Sorry! Image not available at this time

FDA Approves Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

drugs.com - 12/Sep 08:09

South San Francisco, CA -- September 12, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S....

Sorry! Image not available at this time

Over 5 Million Americans Could Benefit If Psilocybin Approved for Depression: Study

drugs.com - 13/Sep 11:00

FRIDAY, Sept. 13, 2024 -- Over 5 million Americans could benefit if the U.S. Food and Drug Administration approves the "magic mushroom" psychedelic...

Sorry! Image not available at this time

Over 5 Million Americans Could Benefit If Psilocybin Approved for Depression: Study

drugs.com - 13/Sep 11:00

FRIDAY, Sept. 13, 2024 -- Over 5 million Americans could benefit if the U.S. Food and Drug Administration approves the "magic mushroom" psychedelic...

Sorry! Image not available at this time

FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

drugs.com - 05:09

South San Francisco, CA -- September 13, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United...

Les derniers communiqués